No abstract

No abstract

Red Cells, Fresh Frozen Plasma (FFP) and Platelets (RDP/SDP) prepared from donors with group O may have high titers of anti-A, anti-B and/or anti-A,B antibodies. When such components given to non-group O patients, this high titre can result in haemolytic transfusion reactions (HTRs). Such group O donors are generally termed ‘high-titer group O donors. Significant amounts of ABO antigen being present on the platelet surface and anti-ABO iso-agglutinins being present in the donor’s plasma, Platelet transfusions need to take into account the issues. Although relatively rare, but acute intravascular haemolytic transfusion reaction has been caused by passive transfer of anti-A and anti-B antibodies, present in group O donors. This study aimed to identify the prevalence of high titre antibodies in group O donors. Thus, titre are performed in randomly selected group O donors from different gender and age group to identify best available source of products for Platelet and follow up transfusions.: Randomly selected 100 O blood group donors were included in the study. Samples from these donors were tested for ABO antibody (both IgM and IgG) titres using conventional tube technique at RT and 37°C at Indirect Antiglobulin phase. Statistical analysis was performed using two sample t-test and anova test.Donors included in the present study were mainly male (85%) donors. ABO antibody titres ranged from 0 to 2048. In the present study, Anti-B (IgG) titer is significantly higher than other antibodies in both genders. There are a large proportion of group O donors having high titres of antibodies and hence a routine pretransfusion screening for such antibodies can prevent the development of hemolytic transfusion reaction by issuing only low titre components for out of group transfusions. Each Blood Transfusion Service should establish a policy for testing and issue of group O platelets to non-O group recipient to avoid chances of development of adverse transfusion reaction.

Internal Quality Control (IQC) describes steps taken by the blood centre to ensure that tests are performed correctly and as per the guidelines. Primary goal of Quality Control is transfusion of safe quality of blood components to give optimal benefit to patients. The aim of study was to ensure supply of safe and efficient blood component to patients.Quality control of blood components prepared between December 2019 to November 2021 were included in our study. Monthly Quality control (QC) of the blood components were done as per the national guideline, 1% of total components prepared or minimum 4 units. Packed red cell units were evaluated for haematocrit, random donor platelet concentrates for yield and fresh frozen plasma (FFP) and cryoprecipitate were evaluated for volume, factor VIII and fibrinogen concentrations.A total of 1302 units were tested for IQC. The mean hematocrit of RBC was 58.8%. In PLT, mean yield was 6.9 × 10/cu mm. Mean factor VIII and fibrinogen levels were found to be 377 IU/bag and 851.60 mg/bag in FFP respectively. Mean factor VIII and fibrinogen levels were found to be 311.81 IU/bag and 1694.4 mg/bag in cryoprecipitate respectively.In the present era, Quality Control is very important step in maintaining quality of blood components and the quality objectives of the blood centre, so that we ensure most efficient blood transfusion to patient. The IQC of blood components at our blood centre is in overall compliance and met recommended national standards. Implementation of standard operating procedures, accomplishment of standard guidelines, proper documentation with regular audit and staff competencies can improve the quality performance of the transfusion services.